Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Crisel

Interventional Cardiology Fayetteville, GA Medical Doctor

NPI 1477714517 CMS profile 462269

1267 Highway 54 W, Suite 2200, Fayetteville, GA 30214

Open in the dashboard

General payments

$12,314

122 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Crisel of Fayetteville, GA is reported in the CMS Open Payments database as having received $12,314 across 122 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $939 22
2024 General $9,600 26
2023 General $793 21
2022 General $281 15
2021 General $367 19
2020 General $86 5
2019 General $248 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Crisel
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Ryan Crisel were reported at $939. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Ryan Crisel Interventional Cardiology median Middle half National median
2019 $248 $1,097 $329–$3,048 $163
2020 $86 $473 $161–$1,480 $114
2021 $367 $677 $233–$1,827 $132
2022 $281 $978 $333–$2,724 $149
2023 $793 $1,136 $382–$2,986 $160
2024 $9,600 $1,181 $395–$3,326 $164
2025 $939 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shockwave Medical, Inc $9,515 22 payments
  2. Medtronic, Inc. $990 13 payments
  3. Novartis Pharmaceuticals Corporation $218 12 payments
  4. Abbott Laboratories $162 5 payments
  5. Pfizer Inc. $149 7 payments
  6. Boston Scientific Corporation $146 5 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $146 9 payments
  8. Inari Medical, Inc. $123 4 payments
  9. Janssen Pharmaceuticals, Inc $108 6 payments
  10. E.R. Squibb & Sons, L.L.C. $85 5 payments
  11. Other $672 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $6,600 1 payment
  2. Food and Beverage $3,593 116 payments
  3. Travel and Lodging $2,075 4 payments
  4. Education $46 1 payment
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $9,396 20 payments
  2. COREVALVE EVOLUT R $448 6 payments
  3. Micra $333 3 payments
  4. ENTRESTO $171 9 payments
  5. LifeVest $146 9 payments
  6. CT THROMBECTOMY SYSTEM KIT $123 4 payments
  7. FLOWTRIEVER CATHETER, S $123 4 payments
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $119 2 payments
  9. AZURE XT DR MRI SURESCAN $110 1 payment
  10. XARELTO $108 6 payments
  11. Other $1,386 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

7,599

Median for Interventional Cardiology: 2,236

Drug cost

$1,312,417

Median for Interventional Cardiology: $380,412

Branded share of claims

27.5%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 436 $482,410
Entresto Sacubitril/Valsartan Brand 292 $319,326
Jardiance Empagliflozin Brand 177 $198,511
Farxiga Dapagliflozin Propanediol Brand 124 $129,292
Xarelto Rivaroxaban Brand 51 $48,772
Repatha Sureclick Evolocumab Brand 20 $30,208
Brilinta Ticagrelor Brand 26 $19,466
Metoprolol Succinate Generic 665 $9,103
Atorvastatin Calcium Generic 877 $7,938
Vascepa Icosapent Ethyl Brand 12 $7,695

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$144,128

Medicare's payments for the services billed

Medicare patients

722

Average age 76

Services billed

2,043

307 women, 415 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Diabetes 42%
Arthritis 41%
Heart failure 37%
Chronic kidney disease 36%
Atrial fibrillation 28%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NEXLETOL
  • Esperion Therapeutics, Inc. $29
$29 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $24
$24 — —
Adempas
  • Bayer HealthCare Pharmaceuticals Inc. $17
$17 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record